Neuleptil (Periciazine)

Periciazine, the active ingredient in Neuleptil, is a phenothiazine presented as an oral formulation for oral use. It is employed to treat schizophrenia and acute psychosis in adult patients.

GNH USA supplies Neuleptil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Periciazine is a typical antipsychotic that acts on dopamine pathways to manage psychotic disorders. - Schizophrenia: reduces hallucinations, delusions and thought disorder. - Acute psychosis: controls sudden emergence of psychotic symptoms and stabilises mental state. - Psychotic disorders (broad): alleviates core psychotic features across related conditions.

Periciazine may cause a range of adverse reactions, some of which are more frequently observed than others.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Dry mouth: reduced salivation leading to discomfort. - Constipation: slowed gastrointestinal motility. - Orthostatic hypotension: dizziness upon standing due to blood pressure drop.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: involuntary, repetitive movements that may be irreversible. - Severe hypotension: marked drop in blood pressure requiring medical attention.

When prescribing periciazine, clinicians should consider several safety measures. - Blood pressure monitoring: watch for orthostatic changes, especially after dose initiation. - Extrapyramidal assessment: evaluate for tremor, rigidity, or abnormal movements. - Cardiac evaluation: review history of arrhythmias or conduction disorders. - Elderly caution: increased risk of sedation and falls in older adults. - Hypersensitivity: discontinue if allergic reactions such as rash or swelling occur. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Periciazine can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines): may enhance sedation and respiratory depression. - Antihypertensives: additive hypotensive effect leading to dizziness or fainting. - Anticholinergic agents: increase risk of severe constipation and urinary retention.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine): may raise periciazine plasma levels. - QT‑prolonging drugs: combined effect could predispose to cardiac arrhythmias.